Importance of Dose Timing to Achieving Undetectable Viral Loads

被引:35
作者
Gill, Christopher J. [1 ,2 ]
Sabin, Lora L. [1 ]
Hamer, Davidson H. [1 ,2 ]
Xu Keyi [3 ]
Zhang Jianbo [4 ]
Li, Tao [1 ]
Wu, Wan-Ju [1 ]
Wilson, Ira B. [5 ]
DeSilva, Mary Bachman [1 ]
机构
[1] Boston Univ Publ Hlth, Ctr Int Hlth & Dev, Crosstown Ctr, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Dept Med, Infect Dis Sect, Boston, MA 02118 USA
[3] Ditan Hosp, Dept Sexually Transmitted Dis & Dermatol, Beijing, Peoples R China
[4] Dali Second Peoples Hosp, Dept Sexually Transmitted Dis & Dermatol, Dali, Peoples R China
[5] Tufts Univ New England Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA USA
关键词
HIV/AIDS; Antiretroviral therapy; Adherence; Dose timing; China; Non nucleoside reverse transcriptase inhibitor; ACTIVE ANTIRETROVIRAL THERAPY; VIROLOGICAL OUTCOMES; INHIBITOR THERAPY; SELF-REPORT; ADHERENCE; MEDICATION; PROTEASE; SUPPRESSION; RESISTANCE;
D O I
10.1007/s10461-009-9555-9
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Little is known about the importance of dose timing to successful antiretroviral therapy (ART). In a cohort comprised of Chinese HIV/AIDS patients, we measured adherence among subjects for 6 months using three methods in parallel: self-report using a visual analog scale (SR-VAS), pill count, and electronic drug monitors (EDM). We calculated two adherence metrics using the EDM data. The first metric used the proportion of doses taken; the second metric credited doses as adherent only if taken within a 1-h window of a pre-specified dose time (EDM 'proportion taken within dose time'). Of the adherence measures, EDM had the strongest associations with viral suppression. Of the two EDM metrics, incorporating dose timing had a stronger association with viral suppression. We conclude that dose timing is also an important determinant of successful ART, and should be considered as an additional dimension to overall adherence.
引用
收藏
页码:785 / 793
页数:9
相关论文
共 26 条
[1]   Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring [J].
Arnsten, JH ;
Demas, PA ;
Farzadegan, H ;
Grant, RW ;
Gourevitch, MN ;
Chang, CJ ;
Buono, D ;
Eckholdt, H ;
Howard, AA ;
Schoenbaum, EE .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) :1417-1423
[2]   Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression [J].
Bangsberg, David R. .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (07) :939-941
[3]   Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness [J].
Bangsberg, DR ;
Acosta, EP ;
Gupta, R ;
Guzman, D ;
Riley, ED ;
Harrigan, PR ;
Parkin, N ;
Deeks, SG .
AIDS, 2006, 20 (02) :223-231
[4]   Non-adherence to highly active antiretroviral therapy predicts progression to AIDS [J].
Bangsberg, DR ;
Perry, S ;
Charlebois, ED ;
Clark, RA ;
Roberston, M ;
Zolopa, AR ;
Moss, A .
AIDS, 2001, 15 (09) :1181-1183
[5]  
de Olalla PG, 2002, J ACQ IMMUN DEF SYND, V30, P105, DOI 10.1097/00042560-200205010-00014
[6]   Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance [J].
Gardner, Edward A. ;
Sharma, Shweta ;
Peng, Grace ;
Hullsiek, Katherine Huppler ;
Burman, William J. ;
MacArthur, Rodger D. ;
Chesney, Margaret ;
Telzak, Edward E. ;
Friedland, Gerald ;
Mannheimer, Sharon B. .
AIDS, 2008, 22 (01) :75-82
[7]   Compliance with tricyclic antidepressants: the value of four different methods of assessment [J].
George, CF ;
Peveler, RC ;
Heiliger, S ;
Thompson, C .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 50 (02) :166-171
[8]  
GILL CJ, 2006, 16 INT AIDS C TOR CA
[9]   Effect of adherence to newly initiated antiretroviral therapy on plasma viral load [J].
Gross, R ;
Bilker, WB ;
Friedman, HM ;
Strom, BL .
AIDS, 2001, 15 (16) :2109-2117
[10]  
Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO